Regeneron tops forecasts, as GAAP profits double for 2nd-qtr

4 August 2015

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) today announced financial results for the second quarter of 2015, and updated on its R&D pipeline, which pleased investors, with significant sales and earnings growth, sending its share up 8.24% to $599.95 by mid-morning.

Total revenues climbed 50% to $999 million for the quarter, beating the forecasts of analysts polled by Zacks Investment Research of 890.9 million. Non-generally accepted account principles (GAAP) net income came in at $338 million, or $2.89 per share, increases of 17%, beating the average estimate of 11 analysts surveyed by Zacks for earnings of $2.68 per share. GAPP income rocketed 103% to $195 million, or $1.69 per share, a rise of 99%.

Hikes US Eylea sales projections

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >